+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

From
From
Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
From
From
Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Advanced Gastric Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Gastric Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
TIM-3 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

TIM-3 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Biliary Tumors Pipeline Analysis Report 2025 - Product Thumbnail Image

Biliary Tumors Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Transitional Cell Carcinoma Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Transitional Cell Carcinoma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
From
Head and Neck Cancer (HNC) Pipeline Analysis Report - Product Thumbnail Image

Head and Neck Cancer (HNC) Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Gastric Cancer Pipeline Analysis Report - Product Thumbnail Image

Gastric Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
From
Hematopoietic Progenitor Kinase 1 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Hematopoietic Progenitor Kinase 1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more